CTNI-14. A 3-ARM, PHASE IIA TRIAL OF SAFETY & EFFICACY OF OLINVACIMAB, A MONOCLONAL ANTIBODY TO VEGFR2 IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME WITH IMAGING AND PK/PD ASSESSMENTS: FINAL REPORT

Eitemau Tebyg

• ACTR-75. A MULTICENTER, 3-ARM, OPEN-LABEL, PHASE IIA CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF TANIBIRUMAB (VEGFR2 MAB), IN PATIENTS WITH RECURRENT GBM ASSESSED WITH K-TRANS AND INITIAL AREA UNDER THE GADOLINIUM CONCENTRATION-TIME CURVE (IAUGC)
  gan: Cher, Lawrence, et al.
  Cyhoeddwyd: (2017)
• CTNI-18. FINAL RESULTS OF A PHASE 2 STUDY OF EFFICACY, SAFETY AND INTRATUMORAL PHARMACOKINETICS (PK) OF SELINEXOR MONOTHERAPY IN RECURRENT GLIOBLASTOMA (rGBM)
  gan: Lassman, Andrew, et al.
  Cyhoeddwyd: (2020)
• VEGFR-2 Expression in Glioblastoma Multiforme Depends on Inflammatory Tumor Microenvironment
  gan: Jaal, Jana, et al.
  Cyhoeddwyd: (2015)
• P01.18 AUTOCRINE VEGFC-VEGFR2 SIGNALING IS OF IMPORTANCE FOR THE GROWTH OF GLIOBLASTOMA MULTIFORME
  gan: Michaelsen, S.R., et al.
  Cyhoeddwyd: (2014)
• CTNI-43. ANLOTINIB COMBINED WITH STUPP REGIMEN IN TREATING PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME: A PHASE II PILOT STUDY
  gan: Lai, Shuzhen, et al.
  Cyhoeddwyd: (2020)